As an incomparable service provider in the in vitro diagnostic (IVD) field, Creative Biolabs offers a full range of high-quality antibody development services targeting the nuclear matrix protein 22. With abundant experience, our professional scientists are confident in providing the best-quality custom-specific contract services.
Nuclear Matrix Protein 22
Nuclear matrix proteins (NMPs) are part of the structural framework of the nucleus and provide support for the nuclear shape. These proteins have also been attributed roles in DNA replication, in ribonucleic acid transcription and in the regulation of gene expression. NMP22 is a component of the nuclear matrix that provides a scaffold on which a number of critical nuclear processes are regulated, including DNA synthesis, RNA transcription, and mitosis. Moreover, NMP22 is also a number of the nuclear mitotic apparatus (NuMA), which is associated with the mitotic spindle and appears to facilitate proper segregation and distribution of chromosomes into daughter cells during cell division.
Fig.1 Nuclear structure and organization. (Rynearson A L., 2011)
Nuclear Matrix Protein 22 Marker of Bladder Cancer
Aberrant expression of certain nuclear matrix proteins has been found in several human cancers, including those involving the colon, prostate, and breast. In addition, apoptosis is accompanied with a release of NMP22 into the urine, and patients with bladder cancer have a significantly elevated concentration of NMP22, reported being as high as 25 times that of normal concentrations. Furthermore, intracellular NMP22 levels correlate with the degree of differentiation of bladder cancer cells. Consideration of these data combined with the fact that aneuploidy and chromosomal aberrations are hallmarks of bladder cancer led to the evaluation of NMP22 as a potential marker of urothelial malignancy.
IVD Antibody Development Services Targeting the NMP22 Marker
NMP22 has been used as a useful marker to aid in the screening of bladder cancer. To promote the in vitro diagnosis of bladder cancer, Creative Biolabs provides a series of IVD antibody development services targeting specific biomarkers of bladder cancer, such as NMP22. With our versatile IVD platform, Creative Biolabs is proud to develop novel NMP22-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates). Our experts will provide the most professional antibody development services to make your project a success.
For more detailed information, please feel free to contact us and get a quote.
Reference
For Research Use Only.
